Welcome to our dedicated page for LIGAND PHARMACEUTICALS SEC filings (Ticker: LGND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LIGAND PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LIGAND PHARMACEUTICALS's regulatory disclosures and financial reporting.
Ligand Pharmaceuticals reported a proposed private placement of $400.0 million aggregate principal amount of convertible senior notes due 2030, with initial purchasers offered a 13-day option to buy up to an additional $60.0 million. The notes are being offered to qualified institutional buyers under Rule 144A and have not been registered under the Securities Act.
The company also entered into a Second Amendment to its Credit Agreement to permit certain cash settlement payments on the notes, subject to customary conditions. The filing includes the amendment and a press release as exhibits, and emphasizes that any offering will be made only by confidential offering memorandum and is not a public solicitation.
Ligand Pharmaceuticals (LGND) reported stronger results in the quarter ended June 30, 2025, with total revenues of $47.6 million, up from $41.5 million a year earlier, driven by higher royalties of $36.4 million and a jump in income from financial royalty assets to $6.3 million from $0.6 million. Operating income for the quarter turned positive at $8.4 million compared with an operating loss a year earlier, reflecting higher royalty receipts and Captisol sales.
Despite the quarterly improvement, the first half of 2025 produced a $51.9 million net loss versus net income of $34.2 million in the prior-year period, largely reflecting non-operating swings and a $44.3 million one-time research and development expense tied to the Castle Creek transaction. Material transactions this period include the Castle Creek investment (Ligand funded $50 million of a $75 million syndicate, allocating $44.3 million to D-Fi royalty rights and $5.8 million to a warrant) and the prior Apeiron acquisition (base consideration $100.5 million with Qarziba royalty assets added). Balance sheet highlights: total assets $948.6 million, cash $67.7 million, and stockholders' equity $828.5 million; Pelthos was classified as held for sale with assets of $35.2 million and related liabilities of $35.7 million.
Ligand Pharmaceuticals (LGND) – Form 4 filing: Chief Financial Officer Octavio Espinoza acquired 224 common shares on 30 June 2025 through the company’s Employee Stock Purchase Plan (ESPP), a transaction coded “J,” which is exempt under Rules 16b-3(c) and 16b-3(d).
The shares were purchased at an average price of $91.08 per share, increasing Espinoza’s direct beneficial ownership to 29,852 shares. No derivative securities were reported in Table II. The filing was signed on 2 July 2025 by an attorney-in-fact on behalf of the executive.
Because the purchase occurred under an automatic ESPP rather than an open-market discretionary trade, the signal for insider sentiment is modest; however, it still marginally aligns executive and shareholder interests.